248 related articles for article (PubMed ID: 1782973)
1. Impact of environmental and genetic factors on codeine analgesia.
Desmeules J; Gascon MP; Dayer P; Magistris M
Eur J Clin Pharmacol; 1991; 41(1):23-6. PubMed ID: 1782973
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).
Dayer P; Desmeules J; Leemann T; Striberni R
Biochem Biophys Res Commun; 1988 Apr; 152(1):411-6. PubMed ID: 3358767
[TBL] [Abstract][Full Text] [Related]
3. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.
Sindrup SH; Hofmann U; Asmussen J; Mikus G; Brøsen K; Nielsen F; Ingwersen SH; Broen Christensen C
Eur J Clin Pharmacol; 1996; 49(6):503-9. PubMed ID: 8706777
[TBL] [Abstract][Full Text] [Related]
4. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
5. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
6. The effect of quinidine on the analgesic effect of codeine.
Sindrup SH; Arendt-Nielsen L; Brøsen K; Bjerring P; Angelo HR; Eriksen B; Gram LF
Eur J Clin Pharmacol; 1992; 42(6):587-91. PubMed ID: 1623898
[TBL] [Abstract][Full Text] [Related]
7. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
8. In vitro forecasting of drugs that may interfere with codeine bioactivation.
Dayer P; Desmeules J; Striberni R
Eur J Drug Metab Pharmacokinet; 1992; 17(2):115-20. PubMed ID: 1425809
[TBL] [Abstract][Full Text] [Related]
9. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
Vevelstad M; Pettersen S; Tallaksen C; Brørs O
Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
11. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
12. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
13. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.
Sindrup SH; Brøsen K; Bjerring P; Arendt-Nielsen L; Larsen U; Angelo HR; Gram LF
Clin Pharmacol Ther; 1990 Dec; 48(6):686-93. PubMed ID: 2249379
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.
Kathiramalainathan K; Kaplan HL; Romach MK; Busto UE; Li NY; Säwe J; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 2000 Aug; 20(4):435-44. PubMed ID: 10917405
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
16. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
17. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
19. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1999 Jul; 290(1):413-22. PubMed ID: 10381807
[TBL] [Abstract][Full Text] [Related]
20. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.
Cleary J; Mikus G; Somogyi A; Bochner F
J Pharmacol Exp Ther; 1994 Dec; 271(3):1528-34. PubMed ID: 7996467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
